BioCentury | Jan 5, 2009
Finance

Restructuring watch

...Cuts primarily coming from R&D; says it plans to sharpens its focus on cancer 10/8/08 Nventa...
BioCentury | Oct 13, 2008
Company News

Nventa infectious, genitourinary, cancer news

...Oct. 1, Nventa had $5.9 million in cash, which it expects to last until 2Q09. Nventa Biopharmaceuticals Corp....
BioCentury | Jun 2, 2008
Company News

Nventa board of directors update

Nventa Biopharmaceuticals Corp. (TSX:NVN), San Diego, Calif. Business: Infectious, Genitourinary, Cancer Appointed: Gordon Busenbark, CFO of Xytis Pharmaceuticals Inc. WIR Staff...
BioCentury | May 26, 2008
Clinical News

HspE7 plus Poly-ICLC: Phase II start

...Mid-year, Nventa plans to start a double-blind, placebo-controlled, North and South American Phase II trial in...
...South American Phase II trial in patients with human papillomavirus (HPV) type 16-induced CIN 2/3. Nventa Biopharmaceuticals Corp....
BioCentury | May 12, 2008
Company News

Nventa board of directors update

Nventa Biopharmaceuticals Corp. (TSX:NVN), San Diego, Calif. Business: Infectious, Genitourinary, Cancer Appointed: John Varian, COO and CFO of ARYx Therapeutics Inc. WIR Staff cancer Genitourinary Infectious...
BioCentury | Apr 28, 2008
Clinical News

HspE7 plus Poly-ICLC: Phase I data

...TLR3) agonist. Data from the first 3 cohorts were previously reported (see BioCentury, March 10). Nventa Biopharmaceuticals Corp....
BioCentury | Mar 31, 2008
Clinical News

HspE7 plus Poly-ICLC: Interim Phase I data

...were previously reported (see BioCentury, Dec. 3, 2007, Jan. 21, 2008 & March 10, 2008). Nventa Biopharmaceuticals Corp....
BioCentury | Mar 17, 2008
Clinical News

HspE7 plus Poly-ICLC: Phase II start

...This year, Nventa will begin a U.S. Phase II trial to evaluate 3 doses of subcutaneous...
...evaluate 3 doses of subcutaneous HspE7 plus Poly-ICLC given over a 60-day period in patients. Nventa Biopharmaceuticals Corp....
BioCentury | Mar 10, 2008
Clinical News

HspE7 plus Poly-ICLC: Interim Phase I data

...first two cohorts were previously reported (see BioCentury, Dec. 3, 2007 & Jan. 21, 2008). Nventa Biopharmaceuticals Corp....
BioCentury | Jan 21, 2008
Clinical News

HspE7 plus adjuvant: Interim Phase I data

...the first cohort of 4 patients were reported last month (see BioCentury, Dec. 3, 2007). Nventa Biopharmaceuticals Corp....
Items per page:
1 - 10 of 161
BioCentury | Jan 5, 2009
Finance

Restructuring watch

...Cuts primarily coming from R&D; says it plans to sharpens its focus on cancer 10/8/08 Nventa...
BioCentury | Oct 13, 2008
Company News

Nventa infectious, genitourinary, cancer news

...Oct. 1, Nventa had $5.9 million in cash, which it expects to last until 2Q09. Nventa Biopharmaceuticals Corp....
BioCentury | Jun 2, 2008
Company News

Nventa board of directors update

Nventa Biopharmaceuticals Corp. (TSX:NVN), San Diego, Calif. Business: Infectious, Genitourinary, Cancer Appointed: Gordon Busenbark, CFO of Xytis Pharmaceuticals Inc. WIR Staff...
BioCentury | May 26, 2008
Clinical News

HspE7 plus Poly-ICLC: Phase II start

...Mid-year, Nventa plans to start a double-blind, placebo-controlled, North and South American Phase II trial in...
...South American Phase II trial in patients with human papillomavirus (HPV) type 16-induced CIN 2/3. Nventa Biopharmaceuticals Corp....
BioCentury | May 12, 2008
Company News

Nventa board of directors update

Nventa Biopharmaceuticals Corp. (TSX:NVN), San Diego, Calif. Business: Infectious, Genitourinary, Cancer Appointed: John Varian, COO and CFO of ARYx Therapeutics Inc. WIR Staff cancer Genitourinary Infectious...
BioCentury | Apr 28, 2008
Clinical News

HspE7 plus Poly-ICLC: Phase I data

...TLR3) agonist. Data from the first 3 cohorts were previously reported (see BioCentury, March 10). Nventa Biopharmaceuticals Corp....
BioCentury | Mar 31, 2008
Clinical News

HspE7 plus Poly-ICLC: Interim Phase I data

...were previously reported (see BioCentury, Dec. 3, 2007, Jan. 21, 2008 & March 10, 2008). Nventa Biopharmaceuticals Corp....
BioCentury | Mar 17, 2008
Clinical News

HspE7 plus Poly-ICLC: Phase II start

...This year, Nventa will begin a U.S. Phase II trial to evaluate 3 doses of subcutaneous...
...evaluate 3 doses of subcutaneous HspE7 plus Poly-ICLC given over a 60-day period in patients. Nventa Biopharmaceuticals Corp....
BioCentury | Mar 10, 2008
Clinical News

HspE7 plus Poly-ICLC: Interim Phase I data

...first two cohorts were previously reported (see BioCentury, Dec. 3, 2007 & Jan. 21, 2008). Nventa Biopharmaceuticals Corp....
BioCentury | Jan 21, 2008
Clinical News

HspE7 plus adjuvant: Interim Phase I data

...the first cohort of 4 patients were reported last month (see BioCentury, Dec. 3, 2007). Nventa Biopharmaceuticals Corp....
Items per page:
1 - 10 of 161